{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:12:34Z","timestamp":1779923554115,"version":"3.53.1"},"reference-count":45,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis C virus (HCV) infection has the greatest health impact in patients with advanced liver disease. The direct\u2010acting antiviral (DAA) regimen glecaprevir\/pibrentasvir (G\/P) is approved for treatment of HCV\u2010infected patients without cirrhosis and with compensated cirrhosis. However, events of liver decompensation\/failure have been reported in patients treated with protease\u2010inhibitor\u2013containing DAA regimens, often in patients with advanced liver disease. This study examines the safety of on\u2010label G\/P treatment in patients with compensated cirrhosis (F4 at baseline) with markers of advanced liver disease. Patients with cirrhosis were categorized into 4 subgroups, based on different noninvasive markers of advanced liver disease identified using laboratory measures: platelet count &lt; or\u2009\u2265\u2009100\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, and Child\u2010Pugh score 5 or 6. Separate analyses were performed using pooled data from clinical trials and from real\u2010world post\u2010marketing observational studies. G\/P was well tolerated in patients with platelet count \u2265100\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L (<jats:italic>n<\/jats:italic>\u00a0=\u00a0800), platelet count &lt;100\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L (<jats:italic>n<\/jats:italic>\u00a0=\u00a0215), a Child\u2010Pugh score of 5 (<jats:italic>n<\/jats:italic>\u00a0=\u00a0915) and a Child\u2010Pugh score of 6 (<jats:italic>n<\/jats:italic>\u00a0=\u00a095). In the clinical trial and real\u2010world cohorts two patients and no patients experienced a serious adverse event (AE) possibly related to study drug, respectively; three patients and no patients experienced an AE of special interest for hepatic decompensation and hepatic failure. This analysis reaffirms G\/P's safety profile in indicated patients with compensated cirrhosis, including those with markers of more advanced liver disease. Increasing the number of patients treated with short\u2010duration G\/P therapy may contribute to meeting HCV elimination targets.<\/jats:p>","DOI":"10.1111\/jvh.13738","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T08:49:15Z","timestamp":1661762955000},"page":"1050-1061","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety analysis of glecaprevir\/pibrentasvir in patients with markers of advanced liver disease in clinical and real\u2010world cohorts"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J.","family":"Feld","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-1764","authenticated-orcid":false,"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Clinic University of Barcelona, IDIBAPS and CIBEREHD  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Dylla","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-1951","authenticated-orcid":false,"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[{"name":"Bordeaux University Hospital  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease  Beijing China"},{"name":"Beijing Tsinghua Changgung Hospital Tsinghua University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert S.","family":"Brown","sequence":"additional","affiliation":[{"name":"Center for Liver Disease and Transplantation Weill Cornell Medical College  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology Medical University of Bia\u0142ystok, Bia\u0142ystok  Bialystok Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, CRC \u201cA. M. and A. Migliavacca\u201d Center for Liver Disease  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re\u2010Charles Foix  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tatsch","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Emmett","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"NYU Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"1","key":"e_1_2_13_2_1","first-page":"68A","article-title":"Global status update on the HCV prevalence and cascade of care entering 2020","volume":"74","author":"Blach S","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2005.05.003"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3055"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.12.001"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60383-9"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13295"},{"issue":"17","key":"e_1_2_13_8_1","first-page":"32273","article-title":"HCV eradication induced by direct\u2010acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"0168","author":"Ioannou GN","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"e_1_2_13_10_1","volume-title":"Global Hepatitis Report","author":"World Health Organization (WHO)","year":"2017"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldx017"},{"key":"e_1_2_13_12_1","volume-title":"Maviret","author":"Maviret EU","year":"2020"},{"key":"e_1_2_13_13_1","volume-title":"Mavyret US","author":"Mavyret US","year":"2019"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.044"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.09.017"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.025"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14537"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29408"},{"key":"e_1_2_13_19_1","unstructured":"US FDA.FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines mavyret zepatier and vosevi in some patients with advanced liver disease.2019."},{"key":"e_1_2_13_20_1","article-title":"No identified association between glecaprevir\/pibrentasvir use and risk of hepatic decompensation in HCV\u2010infected patients with compensated cirrhosis at baseline: an active comparatory cohort study","volume":"38","author":"Wegrzyn L","year":"2019","journal-title":"Presented at Hep Dart"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503074"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.021"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30341-8"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy220"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.09.002"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.020"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30086-8"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02217-17"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01123-0"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14320"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.03.025"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2017.28"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.6011"},{"key":"e_1_2_13_40_1","unstructured":"Royal College of General Practitioners.Guidance for the prevention testing treatment and management of hepatitis C in primary care.2007."},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.06.014"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S172512"},{"issue":"2","key":"e_1_2_13_43_1","first-page":"686","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"AASLD\u2010IDSA Hepatitis C Guidance Panel","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_13_44_1","volume-title":"France Switches to Simplified Pangenotypic Hepatitis C Treatment","author":"Alcorn K.","year":"2019"},{"issue":"1","key":"e_1_2_13_45_1","first-page":"27","article-title":"4\u2009years of direct\u2010acting antivirals (DAAs) in the German hepatitis C\u2010registry (DHC\u2010R)","volume":"57","author":"Huppe D","year":"2019","journal-title":"Z Gastroenterol"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.022"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13738","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:00:34Z","timestamp":1692586834000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/jvh.13738"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13738","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"2022-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}